These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 10440872

  • 1. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesis.
    Frost PJ, Belldegrun A, Bonavida B.
    Prostate; 1999 Sep 15; 41(1):20-30. PubMed ID: 10440872
    [Abstract] [Full Text] [Related]

  • 2. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity.
    Frost P, Ng CP, Belldegrun A, Bonavida B.
    Cell Immunol; 1997 Aug 25; 180(1):70-83. PubMed ID: 9316641
    [Abstract] [Full Text] [Related]

  • 3. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
    Frost PJ, Butterfield LH, Dissette VB, Economou JS, Bonavida B.
    J Immunol; 2001 Mar 01; 166(5):3564-73. PubMed ID: 11207317
    [Abstract] [Full Text] [Related]

  • 4. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
    Uslu R, Borsellino N, Frost P, Gárban H, Ng CP, Mizutani Y, Belldegrun A, Bonavida B.
    Clin Cancer Res; 1997 Jun 01; 3(6):963-72. PubMed ID: 9815772
    [Abstract] [Full Text] [Related]

  • 5. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
    Frost P, Caliliw R, Belldegrun A, Bonavida B.
    Int J Oncol; 2003 Feb 01; 22(2):431-7. PubMed ID: 12527945
    [Abstract] [Full Text] [Related]

  • 6. Adriamycin-mediated potentiation of cytotoxicity against freshly isolated bladder cancer cells by autologous non-activated peripheral blood lymphocytes and tumor infiltrating lymphocytes.
    Mizutani Y, Yoshida O, Miki T.
    J Urol; 1999 Dec 01; 162(6):2170-5. PubMed ID: 10569614
    [Abstract] [Full Text] [Related]

  • 7. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    Mizutani Y, Yoshida O, Bonavida B.
    J Urol; 1998 Aug 01; 160(2):561-70. PubMed ID: 9679929
    [Abstract] [Full Text] [Related]

  • 8. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity.
    Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT.
    J Natl Cancer Inst; 1997 Jun 04; 89(11):783-9. PubMed ID: 9182976
    [Abstract] [Full Text] [Related]

  • 9. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.
    Borsellino N, Belldegrun A, Bonavida B.
    Cancer Res; 1995 Oct 15; 55(20):4633-9. PubMed ID: 7553641
    [Abstract] [Full Text] [Related]

  • 10. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis.
    Uslu R, Jewett A, Bonavida B.
    Gynecol Oncol; 1996 Aug 15; 62(2):282-91. PubMed ID: 8751562
    [Abstract] [Full Text] [Related]

  • 11. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP, Zisman A, Bonavida B.
    Prostate; 2002 Dec 01; 53(4):286-99. PubMed ID: 12430140
    [Abstract] [Full Text] [Related]

  • 12. Potentiation of Fas-mediated apoptosis of murine granulosa cells by interferon-gamma, tumor necrosis factor-alpha, and cycloheximide.
    Quirk SM, Porter DA, Huber SC, Cowan RG.
    Endocrinology; 1998 Dec 01; 139(12):4860-9. PubMed ID: 9832422
    [Abstract] [Full Text] [Related]

  • 13. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis.
    Huerta-Yepez S, Vega M, Garban H, Bonavida B.
    Clin Immunol; 2006 Sep 01; 120(3):297-309. PubMed ID: 16784892
    [Abstract] [Full Text] [Related]

  • 14. Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel.
    Symes JC, Kurin M, Fleshner NE, Medin JA.
    Mol Cancer Ther; 2008 Sep 01; 7(9):3018-28. PubMed ID: 18790782
    [Abstract] [Full Text] [Related]

  • 15. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression.
    Fulda S, Meyer E, Debatin KM.
    Cancer Res; 2000 Jul 15; 60(14):3947-56. PubMed ID: 10919673
    [Abstract] [Full Text] [Related]

  • 16. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
    Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ.
    J Immunol; 2002 Apr 01; 168(7):3484-92. PubMed ID: 11907109
    [Abstract] [Full Text] [Related]

  • 17. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B.
    Clin Cancer Res; 2001 Dec 01; 7(12):3874-83. PubMed ID: 11751478
    [Abstract] [Full Text] [Related]

  • 18. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells.
    Lee RK, Spielman J, Zhao DY, Olsen KJ, Podack ER.
    J Immunol; 1996 Sep 01; 157(5):1919-25. PubMed ID: 8757310
    [Abstract] [Full Text] [Related]

  • 19. Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors.
    Schimmer AD, Thomas MP, Hurren R, Gronda M, Pellecchia M, Pond GR, Konopleva M, Gurfinkel D, Mawji IA, Brown E, Reed JC.
    Cancer Res; 2006 Feb 15; 66(4):2367-75. PubMed ID: 16489043
    [Abstract] [Full Text] [Related]

  • 20. Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes.
    Hishii M, Kurnick JT, Ramirez-Montagut T, Pandolfi F.
    Clin Exp Immunol; 1999 Jun 15; 116(3):388-94. PubMed ID: 10361224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.